Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 45 Triple Negative Breast Neoplasms 1 Sexual Dysfunction, Physiological 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1

Interventions

Paclitaxel 23 Carboplatin 22 Capecitabine 18 Gemcitabine 16 130-nm albumin-bound paclitaxel 16 pembrolizumab 14 Cyclophosphamide 12 atezolizumab 9 Epirubicin 9 sacituzumab govitecan 8 Albumin-Bound Paclitaxel 8 eribulin 6 Vinorelbine 6 Drug Therapy 6 Doxorubicin 6 camrelizumab 4 Docetaxel 4 Cisplatin 4 Injections 3 pegfilgrastim 2 olaparib 2 famitinib 2 Filgrastim 2 Everolimus 2 veliparib 1 trilaciclib 1 toripalimab 1 taxane 1 niraparib 1 ipatasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Triple Negative Breast Neoplasms × bicalutamide × Clear all

NCT03055312 2021-01-28

SYSUCC-007

Sun Yat-sen University

Phase 3 Terminated

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡